All In Biotech

Free tool

FAERS Monitor: Acuvail

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022427 or its brand name (Acuvail, Ketorolac Tromethamine). Reports on generic versions are filed under their own applications.

Reports

4,504

Serious

2,551

57% of reports

Hospitalization

1,289

Death reported

262

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective491
  • drug hypersensitivity301
  • nausea253
  • headache249
  • pain237
  • dyspnoea220
  • fatigue219
  • treatment failure205
  • off label use179
  • vomiting160
  • diarrhoea149
  • eye pain147
  • product dose omission issue146
  • eye irritation139
  • dizziness126

Reports by year received

View as table
YearReports
200443
200570
200669
200764
200883
2009106
2010138
2011180
2012195
201378
201484
2015103
2016306
2017232
2018203
2019278
2020459
2021222
2022301
2023365
2024339
2025345
2026241

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,655 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye painSignal14712.210.41,500
treatment failureSignal20511.610.11,974
eye irritationSignal13911.39.61,295
drug hypersensitivitySignal3017.36.51,635
product dose omission issueSignal1462.32.0110
headache2491.91.6100
dyspnoea2201.81.682
pain2371.81.686
drug ineffective4911.71.6164
vomiting1601.61.435
nausea2531.51.342
fatigue2191.31.217
dizziness1261.21.03
diarrhoea1491.10.91
off label use1791.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.